Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00636545 · ClinicalTrials.gov registry record · Phase 1
Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors
A Phase 1 study, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00636545 is a Phase 1 study that has completed, run by Genta Incorporated. The registered enrollment target is 25 participants.
The verdict
NCT00636545, a Phase 1 study, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective is to determine the safety and maximum tolerated dose (MTD) of Genasense administered as a 2-hour intravenous infusion once weekly (Part 1) and twice weekly (Part 2) to patients with solid tumors.
Interventions
- DRUG Oblimersen (Genasense)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00636545
The ClinicalTrials.gov registry entry for NCT00636545 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genta Incorporated, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oblimersen (Genasense) is the first listed.
NCT00636545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00636545 about?
NCT00636545 is a clinical study titled "Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors". The primary objective is to determine the safety and maximum tolerated dose (MTD) of Genasense administered as a 2-hour intravenous infusion once weekly (Part 1) and twice weekly (Part 2) to patients with solid tumors.
What is the current status of trial NCT00636545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00636545?
The interventions under investigation include: Oblimersen (Genasense) (DRUG).
Who is sponsoring clinical trial NCT00636545?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.